US FDA’s Abernethy Leaves Behind Legacy Of Tech Modernization, Real-World Data
After slightly more than two years as second-in-command, Abernethy says she’s leaving FDA because her initiatives were starting to develop their own momentum. Abernethy, who the agency’s acting chief information officer, worked to modernize FDA’s information technology infrastructure and data capabilities while also exploring confidently using real-world data to support regulatory decision-making.
You may also be interested in...
FDA Launches Digital Modernization Plan To Complement Its Technology Modernization Plan
Agency heads say the new plan will siphon and aggregate more data that could help the regulatory body make better and faster regulatory decisions.
Pandemic Accelerates US FDA’s Use Of Real-World Data From Clinical Trial Design To Supply Chain
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
Real-World Evidence On COVID-19: US FDA Approaching With 'Sense Of Urgency'
Agency is going outside its ‘comfort zone’ to leverage different streams of existing real-world data sources to quickly assess the impact of potential treatment approaches, Amy Abernethy says; pandemic experience could lead to a more open embrace of RWE beyond the current public health emergency.